The MOG35-55 model of EAE is considered the gold standard model in the field and is routinely used in the development of therapeutics for MS. Phenotypes are mediated by self-reactive encephalitogenic T cells, as well as macrophages, resident microglia, and astrocytes. Disease is induced by immunization with a myelin oligodendrocyte glycoprotein (MOG) emulsified in Complete Freund Adjuvant (CFA), followed by Pertussis toxin administration. An ascending flaccid paralysis that begins with a limp tail and progresses to hind and forelimb paralysis is observed. Test article responses can be compared to the effects of Prednisolone or Fingolimod.
MOG-induced EAE animals are weighed daily, and body weight compared to Day 0 is calculated. The AUC is calculated to compare treatment arms and is shown in the inset. (*p<0.05 compared to the vehicle-control)
Animals are evaluated for clinical signs of EAE on a daily basis and are assigned an EAE score. The AUC is calculated to compare treatment arms and is shown in the inset. (*p<0.05; **p<0.01; ***p<0.005 compared to the vehicle-control)
Animals are evaluated for clinical signs of EAE on a daily basis and the overall disease incidence is calculated.